Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
FBIO 
Fortress Biotech Inc (FBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/27/2025: FBIO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10.5
1 Year Target Price $10.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -73.98% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 74.68M USD | Price to earnings Ratio - | 1Y Target Price 10.5 |
Price to earnings Ratio - | 1Y Target Price 10.5 | ||
Volume (30-day avg) 2 | Beta 1.75 | 52 Weeks Range 1.33 - 4.20 | Updated Date 10/27/2025 |
52 Weeks Range 1.33 - 4.20 | Updated Date 10/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.91 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -24.84% | Operating Margin (TTM) -222.22% |
Management Effectiveness
Return on Assets (TTM) -40.94% | Return on Equity (TTM) -784.32% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 78149308 | Price to Sales(TTM) 1.26 |
Enterprise Value 78149308 | Price to Sales(TTM) 1.26 | ||
Enterprise Value to Revenue 1.32 | Enterprise Value to EBITDA -0.29 | Shares Outstanding 29754753 | Shares Floating 22168184 |
Shares Outstanding 29754753 | Shares Floating 22168184 | ||
Percent Insiders 20.98 | Percent Institutions 17.13 |
Upturn AI SWOT
Fortress Biotech Inc
Company Overview
History and Background
Fortress Biotech Inc. was founded in 2006. It focuses on acquiring, developing, and commercializing pharmaceutical and biotechnology products.
Core Business Areas
- Pharmaceutical Development: Acquisition and development of pharmaceutical products and therapies, often focusing on unmet medical needs.
- Commercialization: Bringing approved products to market, often through partnerships or subsidiaries.
- Subsidiary Management: Oversight and management of various subsidiary companies focused on specific therapeutic areas.
Leadership and Structure
Lindsay A. Rosenwald, M.D. is Chairman, President and Chief Executive Officer. The company operates with a structure involving a parent company (Fortress Biotech) and various subsidiaries.
Top Products and Market Share
Key Offerings
- Accutane: Brand name for isotretinoin. The drug is an effective oral treatment option for severe recalcitrant acne. Fortress acquired US rights. Competitors include generic isotretinoin manufacturers.
- Dermatology Products: A broad portfolio of prescription dermatology products. Competitors are many dermatology focused companies.
Market Dynamics
Industry Overview
The pharmaceutical and biotechnology industry is characterized by intense competition, high research and development costs, and stringent regulatory oversight.
Positioning
Fortress Biotech occupies a niche position by acquiring and developing products rather than focusing solely on in-house research and development.
Total Addressable Market (TAM)
The overall pharmaceutical market is substantial. Fortress Biotech's TAM is tied to the specific products it develops and acquires and the indication(s) for which they are approved.
Upturn SWOT Analysis
Strengths
- Diverse Portfolio of Products
- Strategic Acquisitions
- Experienced Management Team
- Subsidiary Model
Weaknesses
- Dependence on Acquisitions
- Limited Internal R&D
- Consistent profitability concerns
- Small market capitalization
Opportunities
- Further Acquisitions of Promising Products
- Partnerships with Larger Pharmaceutical Companies
- Expansion into New Therapeutic Areas
- Regulatory Advancements
Threats
- Competition from Larger Pharmaceutical Companies
- Regulatory Hurdles
- Patent Expirations
- Generic Competition
Competitors and Market Share
Key Competitors
- JAZZ
- ALNY
- AMGN
Competitive Landscape
Fortress Biotech faces intense competition from larger companies with greater resources.
Major Acquisitions
Avenue Therapeutics
- Year: 2018
- Acquisition Price (USD millions): 18.5
- Strategic Rationale: Acquire innovative products.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by acquisitions and product development.
Future Projections: Future growth depends on successful commercialization of existing products and future acquisitions.
Recent Initiatives: Focus on development of clinical assets and commercialization strategy.
Summary
Fortress Biotech is a pharmaceutical company focused on acquiring and developing promising products. Its business model relies on strategic acquisitions. The company must overcome challenges related to intense competition. Future success depends on its ability to commercialize effectively and make strategic acquisitions.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Yahoo Finance
- Analyst Reports (where available)
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share data is estimated and subject to change. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fortress Biotech Inc
Exchange NASDAQ | Headquaters Bay Harbor Islands, FL, United States | ||
IPO Launch date 2011-11-17 | Executive Chairman, President & CEO Dr. Lindsay Allan Rosenwald M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 101 | Website https://www.fortressbiotech.com |
Full time employees 101 | Website https://www.fortressbiotech.com | ||
Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company's early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.